Denis Drygin, Ph.D..

Denis Drygin, Ph.D.

Denis joined Regulus in 2020 and serves as chief scientific officer. Prior to joining Regulus, he was vice president of research & development for Pimera Inc., a privately held biopharmaceutical company of which he is a Founder. Before Pimera, Denis was with Cylene Pharmaceuticals, most recently serving as vice president of biology. With nearly 20 years of experience, Denis led discovery and/or development of multiple therapeutics including the first selective inhibitor of CK2 kinase Silmitasertib (CX-4945), the first selective inhibitor of RNA Polymerase I transcription (Pol I) CX-5461, and the second generation Pol I inhibitor PMR-116. Denis has authored more than 80 book chapters, reviews, manuscripts, abstracts, and patent applications. He received his B.S./M.S. in chemistry from Moscow State University, M.S./Ph.D. in molecular and cellular biology from the University of Massachusetts at Amherst and did his postdoctoral training in pharmacology and toxicology at Ionis Pharmaceuticals.